drugset / Trial / NCT02211443
Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
Non-randomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to determine whether SCT200 is safe and tolerant in the treatment of metastatic colorectal cancer
Timeline
- Start
- 2015-01
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCT200 | Monoclonal antibody | 0.5 mg/kg | Intravenous |
| Subject | SCT200 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | SCT200 | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | SCT200 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | SCT200 | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | SCT200 | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | SCT200 | Monoclonal antibody | 6 mg/kg | Intravenous |